A Two-Biomarker Signal for Alzheimer’s Disease - Report - MDSpire

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

  • By

  • Henry Thomas

  • March 30, 2026

  • 3 min

Share

Clinical Report: A Two-Biomarker Signal for Alzheimer’s Disease

Overview

A prospective cohort study indicates that combining plasma biomarkers p-tau217 and eMTBR-tau243 can enhance the identification of established Alzheimer's disease and predict cognitive decline. This dual biomarker approach demonstrates high accuracy in distinguishing patients with significant tau pathology.

Background

Alzheimer's disease (AD) is a leading cause of dementia, affecting millions globally. Accurate diagnosis and staging of AD are critical for effective management and treatment strategies. Recent advancements in blood-based biomarkers offer promising avenues for improving diagnostic precision and understanding disease progression.

Data Highlights

BiomarkerAccuracyPositive Predictive Value
Combined p-tau217 and eMTBR-tau24381%84%
eMTBR-tau243 for high tau pathology87%N/A

Key Findings

  • The combination of p-tau217 and eMTBR-tau243 improves identification of established Alzheimer's disease.
  • Patients with positive p-tau217 results showed 81% accuracy and 84% positive predictive value when eMTBR-tau243 was added.
  • eMTBR-tau243 demonstrated 87% accuracy in identifying patients with high tau pathology.
  • Higher levels of eMTBR-tau243 were associated with greater tau accumulation and cognitive decline.
  • The study supports a two-step testing strategy for better diagnostic precision.

Clinical Implications

The findings suggest that integrating plasma biomarkers into clinical practice can enhance diagnostic accuracy for Alzheimer's disease. Clinicians may consider using a two-step approach to differentiate between asymptomatic amyloid pathology and clinically significant Alzheimer's disease.

Conclusion

The study underscores the potential of a dual biomarker strategy in improving the diagnosis and understanding of Alzheimer's disease pathology, warranting further research in diverse clinical settings.

References

  1. Brain, Oxford University Press, 2023 -- Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder
  2. Retinal Physician, 2024 -- Retinal Biomarkers for Alzheimer Disease
  3. Acta Neuropathologica, 2014 -- A Biochip Utilizing Platelet Proteins Enables Rapid Identification of Alzheimer’s Disease-Specific Phenotypes
  4. Acta Neuropathologica, 2022 -- Plasma Biomarkers Associated with Alzheimer’s Disease: Links to Neuropathological Changes and Cognitive Decline
  5. Clinical practice guideline for blood‐based biomarkers in the diagnostic workup of Alzheimer’s disease within specialized care settings: A report from the Alzheimer's Association - PMC
  6. FDA, 2025 -- FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease
  7. Nature Medicine, 2025 -- Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
  8. Clinical practice guideline for blood‐based biomarkers in the diagnostic workup of Alzheimer’s disease within specialized care settings: A report from the Alzheimer's Association - PMC
  9. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease | FDA
  10. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease | Nature Medicine

Original Source(s)

A Two-Biomarker Signal for Alzheimer’s Disease

  • by Henry Thomas

  • March 30, 2026

Related Content

Medical Oddities: Brain Health, Sunny-Side Up

Breakfast, bacteria, and brain wiring—small things show big implications this week.

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.